Contributions
Abstract: EP1539
Type: ePoster
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Background: High doses of biotin are reported to improve neurologic function in a small percentage of persons with progressive MS. We wished to document these potential benefits in a “real world” MS specialty clinic.
Objective: To determine the tolerability and efficacy of high dose biotin in persons with progressive MS.
Methods: Three groups of patients with clinically definite multiple sclerosis were evaluated.
Group 1: Patients with relapsing disease, controlled on disease-modifying therapy yet with progressive disability;
Group 2: Patients with secondary progressive MS;
Group 3: Patients with primary progressive disease.
Pharmaceutical grade biotin in 300 mg capsules, prepared by a compounding pharmacy, was prescribed once daily. Neurologic exams and blood work monitoring for toxicity were obtained at baseline and at three-month intervals on drug. Brain MRIs were obtained at baseline and after one year on biotin.
Results: Twenty nine patients were treated. Six had stable relapsing remitting, yet progressive MS. Seventeen had secondary progressive MS, and six had primary progressive MS. Seventeen patients (59%) were women. Patient ages ranged from 31 to 74 years. EDSS scores ranged from 2 to 7. To date, there were no adverse events. Mild improvements in gait, energy, visual acuities and balance were noted after six months of therapy, but improvement regressed to baseline at 9 months of treatment. No major changes in EDSS were noted. One year data will be presented.
Conclusion: High dose biotin, administered daily to persons with progressive MS, is well tolerated and results in a transient improvement of neurologic function in a subset of such individuals.
Disclosure: There is no funding provided for this study.
Gary Birnbaum, MD has nothing to disclose.
Jessica Stulc, MD has nothing to disclose.
Tori Snyder, RN has nothing to disclose
Abstract: EP1539
Type: ePoster
Abstract Category: Therapy - disease modifying - Treatment of progressive MS
Background: High doses of biotin are reported to improve neurologic function in a small percentage of persons with progressive MS. We wished to document these potential benefits in a “real world” MS specialty clinic.
Objective: To determine the tolerability and efficacy of high dose biotin in persons with progressive MS.
Methods: Three groups of patients with clinically definite multiple sclerosis were evaluated.
Group 1: Patients with relapsing disease, controlled on disease-modifying therapy yet with progressive disability;
Group 2: Patients with secondary progressive MS;
Group 3: Patients with primary progressive disease.
Pharmaceutical grade biotin in 300 mg capsules, prepared by a compounding pharmacy, was prescribed once daily. Neurologic exams and blood work monitoring for toxicity were obtained at baseline and at three-month intervals on drug. Brain MRIs were obtained at baseline and after one year on biotin.
Results: Twenty nine patients were treated. Six had stable relapsing remitting, yet progressive MS. Seventeen had secondary progressive MS, and six had primary progressive MS. Seventeen patients (59%) were women. Patient ages ranged from 31 to 74 years. EDSS scores ranged from 2 to 7. To date, there were no adverse events. Mild improvements in gait, energy, visual acuities and balance were noted after six months of therapy, but improvement regressed to baseline at 9 months of treatment. No major changes in EDSS were noted. One year data will be presented.
Conclusion: High dose biotin, administered daily to persons with progressive MS, is well tolerated and results in a transient improvement of neurologic function in a subset of such individuals.
Disclosure: There is no funding provided for this study.
Gary Birnbaum, MD has nothing to disclose.
Jessica Stulc, MD has nothing to disclose.
Tori Snyder, RN has nothing to disclose